EnVVeno Medical Highlights Successful 2024 VEITH Symposium With Launch of Recap Website
EnVVeno Medical Highlights Successful 2024 VEITH Symposium With Launch of Recap Website
Interviews with participating patients from the VenoValve U.S. Pivotal Trial
參與美國VenoValve關鍵試驗的患者採訪
Webcast replay from with the presenting Primary Investigators
與主要調查員一起的網絡轉播重播
Presentation with data from the VenoValve U.S. Pivotal Trial
來自VenoValve美國關鍵試驗的數據展示
Access the Recap Website Here!
在此訪問總結網站!
IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and two Principal Investigators who participated in the VenoValve U.S. Pivotal Trial as well as data presented at the symposium.
2024年11月27日,紐約州長島/ AMEX.股票市場納斯達克/美國戶外廣告協會 (NASDAQ:NVNO)("enVVeno"或"公司"),一家爲治療靜脈疾病制定新標準的公司,今天宣佈推出一個總結網站,重點介紹該公司在最近舉行的第51屆血管和血管內,技術和視野(VEITH)研討會上的參與情況。總結網站提供的材料包括對參與VenoValve美國關鍵試驗的兩名患者和兩名主要調查員的採訪以及在研討會上介紹的數據。
"While our data is compelling, we think it is equally important to hear the stories behind the data from both physicians and patients who have first-hand experience with the VenoValve," said Robert Berman, enVVeno Medical's Chief Executive Officer. "It is physicians and patients that will ultimately drive our commercial success following FDA approval. This is the second group of patients and third group of primary investigators whose perspectives we have made available. It takes an organic network of physician and patient advocates for a new device to succeed and anyone who takes the time to engage with these materials will recognize the strong foundation we've established."
"儘管我們的數據令人信服,但從第一手經驗接觸過VenoValve的醫生和患者那裏聽取數據背後的故事同樣重要,"enVVeno Medical首席執行官Robert Berman說。“最終將推動我們的商業成功的是醫生和患者。這是我們提供的第二組患者和第三組主要調查員的觀點。要使一個新器械成功,需要一支由醫生和患者倡導者構成的有機網絡,任何花時間接觸這些材料的人都將認識到我們已建立的堅實基礎。"
Access the enVVeno Medical VEITH Symposium Recap Site at envveno.com/veith-2024
在envveno.com/veith-2024訪問enVVeno Medical VEITH研討會總結網站
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year.
嚴重的深部靜脈慢性靜脈功能不全(CVI)是一種嚴重的疾病,通常是由於大腿深部靜脈中的血凝塊(深靜脈血栓或DVT)引起的。當大腿靜脈內的瓣膜失效時,血液流向錯誤的方向並在下肢積聚,導致大腿靜脈內壓力增加(靜脈高壓)。嚴重CVI的症狀包括大腿腫脹、疼痛、水腫,以及在最嚴重的情況下,被稱爲靜脈潰瘍的反覆出現的開放性潰瘍。這種疾病嚴重影響了日常功能,如睡眠、洗澡、穿衣和行走,並且已知會導致高發病率的抑鬱症和焦慮症。目前對由瓣膜功能不全引起的深部靜脈系統的嚴重CVI沒有有效的治療方法。估計CVI每年會給美國醫療系統帶來超過40億美元的費用。
The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company is also developing enVVe, a next-generation, transcatheter based replacement venous valve, that could appeal to an even larger market in terms of both patients and physicians.
VenoValve是一種潛在的首創手術替代靜脈瓣膜,適用於患有嚴重深部靜脈CVI的患者。公司估計美國每年約有250萬潛在新患者可能成爲VenoValve的候選人。公司還正在開發enVVe,一種下一代經導管替代靜脈瓣膜,可能吸引更廣泛的市場,無論是患者還是醫生。
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
關於enVVeno Medical Corporation
enVVeno Medical(納斯達克:NVNO)是一家位於加利福尼亞州爾灣的醫療器械公司,專注於推動創新生物修復(基於組織的)解決方案,以改善靜脈疾病的治療標準。該公司的主打產品VenoValve是一種首創的手術替代靜脈瓣膜,用於治療深部靜脈慢性靜脈功能不全(CVI)。公司還在開發一種非手術的基於導管的替代靜脈瓣膜,用於治療深部靜脈CVI,名爲enVVe。CVI發生在大腿靜脈內的瓣膜受損時,導致血液回流(逆流),在下肢積聚,增加大腿靜脈內的壓力(靜脈高壓),在嚴重情況下,會出現難以癒合並變成慢性的靜脈潰瘍。VenoValve和enVVe均設計爲單向閥,可幫助推動血液沿着腿上移動,並返回心臟和肺部。VenoValve目前正在進行SAVVE美國關鍵研究的評估,公司目前正在進行必要的最終測試,以尋求enVVe關鍵試驗的批准。
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
前瞻性聲明的警示說明
本新聞稿和enVVeno Medical Corporation(以下簡稱「公司」)的股東、董事、員工、代表和合作夥伴可能包含或包含其他內容, 根據1995年《證券訴訟改革法》的規定,可能包含某些「前瞻性聲明」。這些前瞻性聲明涉及重大風險和不確定性。此類聲明可能包括但不限於, 由諸如「項目」,「可能」,「將」,「可以」,「應該」,「相信」,「期望」,「預計」,「估計」,「意圖」,「計劃」,「潛在」或類似表達識別的聲明。這些聲明基於公司管理層目前的信念和期望, 並受到重大風險和不確定性的影響,包括在公司向證券交易委員會提交的備案中詳細披露的風險。實際結果和時間可能與前瞻性聲明中設定或暗示的結果大不相同。前瞻性聲明涉及某些風險和不確定性,這些風險和不確定性可能根據各種因素(其中許多超出公司的控制範圍)而發生變化。除非按照適用法律的規定,公司無義務公開更新任何前瞻性聲明,無論是基於新信息、未來演示或其他原因。
###
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
投資者聯繫方式:
Jenene Thomas,JTC Team,LLC
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
來源:enVVeno Medical Corporation